Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.

ABSTRACT:

Background

Trabectedin, which is approved for advanced soft tissue sarcoma management, has a complex mechanism of action, but can be classified as an alkylating agent. The need to maintain a high relative dose intensity (RDI) is not clearly established in this clinical setting.

Methods

We conducted a retrospective study in five expert centers to compare the progression-free survival (PFS) and overall survival (OS) of patients with advanced L-Sarcomas (liposarcomas or leiomyosarcoma) according to the RDI calculated over the first three cycles (RDI < 80% and RDI ≥ 80%). Comparisons of patients' characteristics were done using Chi-2, Fisher exact, and Wilcoxon tests. Associations between PFS/OS and RDI were estimated and tested in Cox models.

Results

Out of 332 patients

SUBMITTER: Poitureau S 

PROVIDER: S-EPMC12361930 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature